Our IHC results confirmed that high expression of CRABP2 in tumor tissues was associated with a poorer prognosis, and multivariate survival analysis identified CRABP2 as an independent prognostic factor for serous ovarian cancer. This evidence concerns the gene CRABP2 and neoplasm.